General
Preferred name
BROMAZEPAM
Synonyms
Lexatin ()
Bromazepam civ ()
NSC-140669 ()
RO-5-3350 ()
Lexotan ()
RO 5-3350 ()
Lexotanil ()
P&D ID
PD009477
CAS
1812-30-2
Tags
natural product
drug
available
First approval
1974
Drug indication
Panic attacks
Tranquilizer (minor)
Anxiety disorder
Drug Status
illicit
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Bromazepam binds to the GABA-A receptor producing a conformational change and potentiating its inhibitory effects. Other neurotransmitters are not influenced.
PHARMACODYNAMICS Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam, like other benzodiazepines, presents a risk of abuse, misuse, and dependence. According to many psychiatric experts, Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.
Compound Sets
11
Cayman Chemical Bioactives
14260
ChEMBL Approved Drugs
CHEMBL277062
ChEMBL Drugs
CHEMBL277062
DrugBank
DB01558
DrugBank Approved Drugs
DB01558
DrugCentral
399
DrugCentral Approved Drugs
399
DrugMAP
DMY9TCW
DrugMAP Approved Drugs
DMY9TCW
DrugMatrix
ReFrame library
External IDs
29
Properties
(calculated by RDKit )
Molecular Weight
315.0
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
3
Aromatic Ring Count
2
cLogP
2.63
TPSA
54.35
Fraction CSP3
0.07
Chiral centers
0.0
Largest ring
7.0
QED
0.88
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Therapeutic Class
Hypnotics and Sedatives
Source data